Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.1.284NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.351.3 (Beta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.318NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
R.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.29 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
ML.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.283NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BE.12NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.96NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.547NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.247NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.4.6NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.205NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.110NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.434NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.4.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.181NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.6.6NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.37NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.513NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.338NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.284NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.9.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.498NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.184NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.187NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
D.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AE.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.110.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.342NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.500NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.511NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.428.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.506NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.482NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.335NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.36.36NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-12070.6US
B.1.499.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.38NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.116NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.134NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.393NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.381NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
C.32NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AE.8NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.516NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.526NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.279NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AE.7NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used